{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:38:21Z","timestamp":1777448301041,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00059-018-4712-4","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T05:27:50Z","timestamp":1526621270000},"page":"383-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current drug therapy for heart failure with reduced ejection fraction","Medikament\u00f6se Therapie der Herzinsuffizienz mit reduzierter systolischer LV-Funktion"],"prefix":"10.1007","volume":"43","author":[{"given":"D.","family":"Berliner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hallbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,18]]},"reference":[{"key":"4712_CR1","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/ejhf.584","volume":"18","author":"KF Adams","year":"2016","unstructured":"Adams KF, Butler J, Patterson JH et\u00a0al (2016) Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Eur J Heart Fail 18:1072\u20131081","journal-title":"Eur J Heart Fail"},{"key":"4712_CR2","doi-asserted-by":"publisher","first-page":"i5","DOI":"10.1093\/eurjhf\/hfp009","volume":"8","author":"CE Angermann","year":"2009","unstructured":"Angermann CE (2009) Comorbidities in heart failure: a\u00a0key issue. Eur J Heart Fail Suppl 8:i5\u2013i10","journal-title":"Eur J Heart Fail Suppl"},{"key":"4712_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0828-282X(06)70237-9","volume":"22","author":"JMO Arnold","year":"2006","unstructured":"Arnold JMO, Liu P, Demers C et\u00a0al (2006) Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 22:23\u201345","journal-title":"Can J Cardiol"},{"key":"4712_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","volume":"65","author":"J Bauersachs","year":"2015","unstructured":"Bauersachs J, Jaisser F, Toto R (2015) Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 65:257\u2013263","journal-title":"Hypertension"},{"issue":"3","key":"4712_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00059-018-4682-6","volume":"43","author":"J Bauersachs","year":"2018","unstructured":"Bauersachs J, Wehling M (2018) Cardiovascular pharmacotherapy in the elderly: To avoid overtreatment and undertherapy. Herz 43(3):195\u2013196. \n                    https:\/\/doi.org\/10.1007\/s00059-018-4682-6","journal-title":"Herz"},{"key":"4712_CR6","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1093\/eurheartj\/ehx493.P6168","volume":"38","author":"U Bavendiek","year":"2017","unstructured":"Bavendiek U, Aguirre Davila L, Koch A et\u00a0al (2017) Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart\u00a0J 38:2095\u20132099","journal-title":"Eur Heart J"},{"key":"4712_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4070\/kcj.2017.0030","volume":"47","author":"D Berliner","year":"2017","unstructured":"Berliner D, Bauersachs J (2017) Current drug therapy in chronic heart failure: the new guidelines of the European Society of Cardiology (ESC). Korean Circ\u00a0J 47:543\u2013554","journal-title":"Korean Circ J"},{"key":"4712_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-017-4668-9","author":"D Berliner","year":"2018","unstructured":"Berliner D, Bauersachs J (2018) Drug treatment of heart failure in the elderly. Herz 43(3):207-213. \n                    https:\/\/doi.org\/10.1007\/s00059-017-4668-9","journal-title":"Herz"},{"key":"4712_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","volume":"102","author":"M Bohm","year":"2013","unstructured":"Bohm M, Borer J, Ford I et\u00a0al (2013) Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 102:11\u201322","journal-title":"Clin Res Cardiol"},{"key":"4712_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14797\/mdcj-9-1-3","volume":"9","author":"B Bozkurt","year":"2013","unstructured":"Bozkurt B, Mann DL (2013) The treatment of heart failure in the 21st century: is the glass half empty or half full? Methodist Debakey Cardiovasc\u00a0J 9:3\u20135","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"4712_CR11","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2017 [cited: 2017-11-11]) Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz \u2013 Langfassung, 2.\u00a0Auflage. Version 2."},{"key":"4712_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ejhf.687","volume":"19","author":"JA Cannon","year":"2017","unstructured":"Cannon JA, Shen L, Jhund PS et al (2017) Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail 19:129\u2013137","journal-title":"Eur J Heart Fail"},{"key":"4712_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","unstructured":"CIBIS-II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a\u00a0randomised trial. Lancet 353:9\u201313","journal-title":"Lancet"},{"key":"4712_CR14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ejhf.799","volume":"19","author":"E D\u2019Elia","year":"2017","unstructured":"D\u2019Elia E, Iacovoni A, Vaduganathan M et\u00a0al (2017) Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail 19:710\u2013717","journal-title":"Eur J Heart Fail"},{"key":"4712_CR15","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.jacc.2015.08.877","volume":"66","author":"GW Dec","year":"2015","unstructured":"Dec GW (2015) LCZ696 (Sacubitril\/Valsartan)\u2014Can we predict who will benefit? J\u00a0Am Coll Cardiol 66:2072\u20132074","journal-title":"J Am Coll Cardiol"},{"key":"4712_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"Investigation Group","year":"1997","unstructured":"Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N\u00a0Engl J Med 336:525\u2013533","journal-title":"N Engl J Med"},{"key":"4712_CR17","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","volume":"32","author":"I Ekman","year":"2011","unstructured":"Ekman I, Chassany O, Komajda M et\u00a0al (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart\u00a0J 32:2395\u20132404","journal-title":"Eur Heart J"},{"key":"4712_CR18","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","volume":"62","author":"R Eschalier","year":"2013","unstructured":"Eschalier R, McMurray JJ, Swedberg K et al (2013) Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J\u00a0Am Coll Cardiol 62:1585\u20131593","journal-title":"J Am Coll Cardiol"},{"key":"4712_CR19","volume-title":"Heart failure: 150 questions & answers","author":"R Ferrari","year":"2011","unstructured":"Ferrari R, Ceconi C, Tavazzi L et al (2011) Heart failure: 150 questions & answers. Servier, Neuilly-sur-Seine Cedex"},{"key":"4712_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ et\u00a0al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart\u00a0J 26:215\u2013225","journal-title":"Eur Heart J"},{"key":"4712_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00392-017-1115-0","volume":"106","author":"H Frohlich","year":"2017","unstructured":"Frohlich H, Torres L, Tager T et\u00a0al (2017) Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clin Res Cardiol 106:711\u2013721","journal-title":"Clin Res Cardiol"},{"key":"4712_CR22","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1001\/jama.2013.1954","volume":"309","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, Bohm M, Greene SJ et\u00a0al (2013) Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309:1125\u20131135","journal-title":"JAMA"},{"key":"4712_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ejhf.1024","volume":"20","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Mentz RJ (2018) Potential advantages of torsemide in patients with heart failure: more than just a\u00a0\u2018water pill\u2019? Eur J Heart Fail 20:471\u2013473","journal-title":"Eur J Heart Fail"},{"key":"4712_CR24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","volume":"283","author":"A Hjalmarson","year":"2000","unstructured":"Hjalmarson A, Goldstein S, Fagerberg B et al (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group. JAMA 283:1295\u20131302","journal-title":"JAMA"},{"key":"4712_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2010.04.004","volume":"16","author":"J Lindenfeld","year":"2010","unstructured":"Lindenfeld J, Albert NM, Boehmer JP et\u00a0al (2010) HFSA 2010 comprehensive heart failure practice guideline. J\u00a0Card Fail 16:e1\u2013e194","journal-title":"J Card Fail"},{"key":"4712_CR26","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Anker SD, Dahlstr\u00f6m U et al (2013) Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15:1173\u20131184","journal-title":"Eur J Heart Fail"},{"key":"4712_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11897-014-0186-8","volume":"11","author":"V Mastromarino","year":"2014","unstructured":"Mastromarino V, Casenghi M, Testa M et\u00a0al (2014) Polypharmacy in heart failure patients. Curr Heart Fail Rep 11:212\u2013219","journal-title":"Curr Heart Fail Rep"},{"key":"4712_CR28","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","volume":"374","author":"JJ McMurray","year":"2016","unstructured":"McMurray JJ, Krum H, Abraham WT et\u00a0al (2016) Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N\u00a0Engl J Med 374:1521\u20131532","journal-title":"N Engl J Med"},{"key":"4712_CR29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"key":"4712_CR30","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","volume":"93","author":"A Mosterd","year":"2007","unstructured":"Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137\u20131146","journal-title":"Heart"},{"key":"4712_CR31","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD et al (2017) Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a\u00a0prospective European study. Eur Heart\u00a0J 38:1883\u20131890","journal-title":"Eur Heart J"},{"key":"4712_CR32","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB et\u00a0al (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194\u20132199","journal-title":"Circulation"},{"key":"4712_CR33","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","volume":"100","author":"M Packer","year":"1999","unstructured":"Packer M, Poole-Wilson PA, Armstrong PW et al (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group. Circulation 100:2312\u20132318","journal-title":"Circulation"},{"key":"4712_CR34","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","volume":"134","author":"RL Page 2nd","year":"2016","unstructured":"Page RL 2nd, O\u2019Bryant CL, Cheng D et\u00a0al (2016) Drugs that May cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 134:e32\u2013e69","journal-title":"Circulation"},{"key":"4712_CR35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA et al (2011) Evaluation of the efficacy and safety of RLY5016, a\u00a0polymeric potassium binder, in a\u00a0double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart\u00a0J 32:820\u2013828","journal-title":"Eur Heart J"},{"key":"4712_CR36","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ejhf.402","volume":"17","author":"B Pitt","year":"2015","unstructured":"Pitt B, Bakris GL, Bushinsky DA et\u00a0al (2015) Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 17:1057\u20131065","journal-title":"Eur J Heart Fail"},{"key":"4712_CR37","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F et\u00a0al (2003) Eplerenone, a\u00a0selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N\u00a0Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"},{"key":"4712_CR38","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et\u00a0al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N\u00a0Engl J Med 341:709\u2013717","journal-title":"N Engl J Med"},{"key":"4712_CR39","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et\u00a0al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891\u2013975","journal-title":"Eur J Heart Fail"},{"key":"4712_CR40","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ejhf.548","volume":"18","author":"M Senni","year":"2016","unstructured":"Senni M, McMurray JJ, Wachter R et al (2016) Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a\u00a0double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail 18:1193\u20131202","journal-title":"Eur J Heart Fail"},{"key":"4712_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1742-1241.2006.00817.x","volume":"60","author":"S Sulfi","year":"2006","unstructured":"Sulfi S, Timmis AD (2006) Ivabradine\u2014the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int J Clin Pract 60:222\u2013228","journal-title":"Int J Clin Pract"},{"key":"4712_CR42","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a\u00a0randomised placebo-controlled study. Lancet 376:875\u2013885","journal-title":"Lancet"},{"key":"4712_CR43","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","volume":"32","author":"JC Tardif","year":"2011","unstructured":"Tardif JC, O\u2019Meara E, Komajda M et\u00a0al (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart\u00a0J 32:2507\u20132515","journal-title":"Eur Heart J"},{"key":"4712_CR44","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","volume":"372","author":"L Tavazzi","year":"2008","unstructured":"Tavazzi L, Maggioni AP, Marchioli R et al (2008) Effect of n\u20113 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 372:1223\u20131230","journal-title":"Lancet"},{"key":"4712_CR45","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/eurjhf\/hft102","volume":"15","author":"L Tavazzi","year":"2013","unstructured":"Tavazzi L, Swedberg K, Komajda M et\u00a0al (2013) Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail 15:1296\u20131303","journal-title":"Eur J Heart Fail"},{"key":"4712_CR46","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","unstructured":"The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N\u00a0Engl J Med 316:1429\u20131435","journal-title":"N Engl J Med"},{"key":"4712_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"SOLVD Investigators","year":"1991","unstructured":"SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N\u00a0Engl J Med 325:293\u2013302","journal-title":"N Engl J Med"},{"key":"4712_CR48","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1042\/CS20060275","volume":"112","author":"MJ Young","year":"2007","unstructured":"Young MJ, Lam EY, Rickard AJ (2007) Mineralocorticoid receptor activation and cardiac fibrosis. Clin Sci 112:467\u2013475","journal-title":"Clin. Sci."},{"key":"4712_CR49","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","volume":"33","author":"F Zannad","year":"2012","unstructured":"Zannad F, Gattis Stough W, Rossignol P et\u00a0al (2012) Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart\u00a0J 33:2782\u20132795","journal-title":"Eur Heart J"},{"key":"4712_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H et\u00a0al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N\u00a0Engl J Med 364:11\u201321","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-018-4712-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4712-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4712-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T01:56:20Z","timestamp":1558144580000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-018-4712-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,18]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4712"],"URL":"https:\/\/doi.org\/10.1007\/s00059-018-4712-4","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,18]]},"assertion":[{"value":"18 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"D.\u00a0Berliner received honoraria and\/or travel support from the following companies and\/or is a member of their advisory boards: Novartis, Abbott, Daiichi Sankyo, Bayer and Boehringer Ingelheim. M.\u00a0Hallbaum received honoraria for advice and travel support from St. Jude Medical\/Abbott, Vifor, CVRx and Bristol Meyer Squibb. J.\u00a0Bauersachs received honoraria for lectures and advice from Novartis, Pfizer, Vifor, Bayer, Servier, Orion, CVRx, Abbott\/SJM\/Thoratec and Medtronic\/Heartware, and research support from Zoll, CVRx, Bayer, Vifor, Abiomed and Medtronic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}